viloxazine (BioDeep_00000271111)

   


代谢物信息卡片


2-[(2-ethoxyphenoxy)methyl]morpholine

化学式: C13H19NO3 (237.1364864)
中文名称: 维洛沙秦
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCOc(c2)c(ccc2)OCC(C1)OCCN1
InChI: InChI=1S/C13H19NO3/c1-2-15-12-5-3-4-6-13(12)17-10-11-9-14-7-8-16-11/h3-6,11,14H,2,7-10H2,1H3

描述信息

D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor
D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents
C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent
N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents
D049990 - Membrane Transport Modulators

同义名列表

2 个代谢物同义名

2-[(2-ethoxyphenoxy)methyl]morpholine; viloxazine



数据库引用编号

15 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Shamia L Faison, Nicholas Fry, Toyin Adewole, Oyinkansola Odebo, Stefan Schwabe, Zhao Wang, Vladimir Maletic, Azmi Nasser. Pharmacokinetics of Coadministered Viloxazine Extended-Release (SPN-812) and Methylphenidate in Healthy Adults. Clinical drug investigation. 2021 Feb; 41(2):149-159. doi: 10.1007/s40261-020-00992-6. [PMID: 33368026]
  • Azmi Nasser, Shamia L Faison, Tesfaye Liranso, Toyin Adewole, Gregory D Busse, Maurizio Fava, Robert B Kleiman, Stefan Schwabe. Evaluation of the Effect of SPN-812 (Viloxazine Extended-Release) on QTc Interval in Healthy Adults. The Journal of clinical psychiatry. 2020 10; 81(6):. doi: 10.4088/jcp.20m13395. [PMID: 33049804]
  • Guoxun Zheng, Weiwei Xue, Panpan Wang, Fengyuan Yang, Bo Li, Xiaofeng Li, Yinghong Li, Xiaojun Yao, Feng Zhu. Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study. Scientific reports. 2016 05; 6(?):26883. doi: 10.1038/srep26883. [PMID: 27230580]
  • Gbolagade Sunmaila Akintomide, Hugh Rickards. Narcolepsy: a review. Neuropsychiatric disease and treatment. 2011; 7(?):507-18. doi: 10.2147/ndt.s23624. [PMID: 21931493]
  • Sarah M R Wille, Els A De Letter, Michel H A Piette, Lien K Van Overschelde, Carlos H Van Peteghem, Willy E Lambert. Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry. International journal of legal medicine. 2009 Nov; 123(6):451-8. doi: 10.1007/s00414-008-0287-6. [PMID: 18839201]
  • R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals. 2008 Jul; 36(7):1385-405. doi: 10.1124/dmd.108.020479. [PMID: 18426954]
  • Sarah M R Wille, Paul Van Hee, Hugo M Neels, Carlos H Van Peteghem, Willy E Lambert. Comparison of electron and chemical ionization modes by validation of a quantitative gas chromatographic-mass spectrometric assay of new generation antidepressants and their active metabolites in plasma. Journal of chromatography. A. 2007 Dec; 1176(1-2):236-45. doi: 10.1016/j.chroma.2007.10.096. [PMID: 18022628]
  • H Kirchherr, W N Kühn-Velten. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: a multi-level, single-sample approach. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2006 Oct; 843(1):100-13. doi: 10.1016/j.jchromb.2006.05.031. [PMID: 16798119]
  • Sarah M R Wille, Kristof E Maudens, Carlos H Van Peteghem, Willy E E Lambert. Development of a solid phase extraction for 13 'new' generation antidepressants and their active metabolites for gas chromatographic-mass spectrometric analysis. Journal of chromatography. A. 2005 Dec; 1098(1-2):19-29. doi: 10.1016/j.chroma.2005.08.059. [PMID: 16314157]
  • Guido Mannaioni, Roberto Baronti, Flavio Moroni. Gastrointestinal bleeding and massive liver damage in neuroleptic malignant syndrome. Therapeutics and clinical risk management. 2005 Sep; 1(3):225-30. doi: NULL. [PMID: 18360563]
  • Pierre Baumann, Sven Ulrich, Gabriel Eckermann, Manfred Gerlach, Hans-Joachim Kuss, Gerd Laux, Bruno Müller-Oerlinghausen, Marie Luise Rao, Peter Riederer, Gerald Zernig, Christoph Hiemke. The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. Dialogues in clinical neuroscience. 2005; 7(3):231-47. doi: NULL. [PMID: 16156382]
  • Charlotte Duverneuil, Geoffroy Lorin de la Grandmaison, Philippe de Mazancourt, Jean-Claude Alvarez. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Therapeutic drug monitoring. 2003 Oct; 25(5):565-73. doi: 10.1097/00007691-200310000-00005. [PMID: 14508379]
  • S Kasper, F Müller-Spahn. Intravenous antidepressant treatment: focus on citalopram. European archives of psychiatry and clinical neuroscience. 2002 Jun; 252(3):105-9. doi: 10.1007/s00406-002-0363-8. [PMID: 12192466]
  • Edoardo Spina, Emilio Perucca. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002; 43 Suppl 2(?):37-44. doi: 10.1046/j.1528-1157.2002.043s2037.x. [PMID: 11903482]
  • C Lestra, T d'Amato, C Ghaemmaghami, A Perret-Liaudet, M Broyer, B Renaud, J Dalery, G Chamba. Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome. Biological psychiatry. 1998 Aug; 44(4):274-80. doi: 10.1016/s0006-3223(97)00389-2. [PMID: 9715359]
  • J Fritze, M Lanczik, E Sofic, M Struck, P Riederer. Cholinergic neurotransmission seems not to be involved in depression but possibly in personality. Journal of psychiatry & neuroscience : JPN. 1995 Jan; 20(1):39-48. doi: . [PMID: 7865500]
  • F Pisani, A Fazio, G Oteri, C Artesi, B Xiao, E Perucca, R Di Perri. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta neurologica Scandinavica. 1994 Aug; 90(2):130-2. doi: 10.1111/j.1600-0404.1994.tb02692.x. [PMID: 7801739]
  • P Thomare, M Bourin, M F Kergueris, A Ortega, C Larousse. Effects of administration route on pharmacokinetics of viloxazine in the rabbit. Methods and findings in experimental and clinical pharmacology. 1992 Mar; 14(2):125-9. doi: NULL. [PMID: 1598024]
  • F Pisani, A Fazio, C Artesi, M Russo, R Trio, G Oteri, E Perucca, R Di Perri. Elevation of plasma phenytoin by viloxazine in epileptic patients: a clinically significant drug interaction. Journal of neurology, neurosurgery, and psychiatry. 1992 Feb; 55(2):126-7. doi: 10.1136/jnnp.55.2.126. [PMID: 1538217]
  • M Candito, D Pringuey, A Iordache, E Souêtre, P Chambon, G Darcourt. Circadian variation in total plasma tryptophan. Antidepressant treatment: drugs and phase advance. Life sciences. 1992; 50(13):PL71-4. doi: 10.1016/0024-3205(92)90178-r. [PMID: 1548974]
  • P Thomare, M F Kergueris, M Bourin, L Thomas, C Larousse. Sensitive one-step extraction procedure for high-performance liquid chromatographic determination of viloxazine in human plasma. Journal of chromatography. 1990 Aug; 529(2):494-9. doi: 10.1016/s0378-4347(00)83860-8. [PMID: 2229267]
  • M C Perault, E Griesemann, S Bouquet, J Lavoisy, B Vandel. A study of the interaction of viloxazine with theophylline. Therapeutic drug monitoring. 1989 Sep; 11(5):520-2. doi: NULL. [PMID: 2815226]
  • S Bouquet, B Vandel, S Guibert, J Lavoisy. [Clinical pharmacokinetics of viloxazine chlorhydrate. Practical implications]. L'Encephale. 1989 Sep; 15(5):443-7. doi: NULL. [PMID: 2686964]
  • M F Kergueris, M Bourin, M Ribeyrol, N Beneroso, Y L Normand, C Larousse. Comparative pharmacokinetic study of conventional and sustained-release viloxazine in normal volunteers. Neuropsychobiology. 1989; 20(3):136-40. doi: 10.1159/000118487. [PMID: 2761683]
  • M Candito, D Pringuey, E Souetre, E Salvati, D Halfon, P Chambon, G Darcourt. [Circadian rhythm of plasma norepinephrine in depressive disorders. Preliminary study]. L'Encephale. 1987 Nov; 13(6):341-7. doi: NULL. [PMID: 3131111]
  • C J Bieva, I H Ladmirant, I Scheirs, J P Dardenne. Administered viloxazine interferes in liquid-chromatographic assay of normetanephrines. Clinical chemistry. 1987 Sep; 33(9):1677-8. doi: NULL. [PMID: 3621582]
  • G L Corona, P Frattini, M L Cucchi, G Santagostino, S Schinelli, F Zerbi, S Cairoli, P Tosca, F Savoldi. Viloxazine in depressed women: clinical response and cardiovascular effects. International journal of clinical pharmacology, therapy, and toxicology. 1987 Jun; 25(6):322-7. doi: NULL. [PMID: 3623737]
  • F Pisani, A Fazio, G Oteri, E Perucca, M Russo, R Trio, B Pisani, R Di Perri. Carbamazepine-viloxazine interaction in patients with epilepsy. Journal of neurology, neurosurgery, and psychiatry. 1986 Oct; 49(10):1142-5. doi: 10.1136/jnnp.49.10.1142. [PMID: 3783175]
  • A C Altamura, M C Mauri, G Guercetti. Age, therapeutic 'milieu' and clinical outcome in depressive patients treated with viloxazine: a study with plasma levels. Progress in neuro-psychopharmacology & biological psychiatry. 1986; 10(1):67-75. doi: 10.1016/0278-5846(86)90045-x. [PMID: 3704174]
  • F Pisani, A Fazio, E Spina, C Artesi, B Pisani, M Russo, R Trio, E Perucca. Pharmacokinetics of the antidepressant drug viloxazine in normal subjects and in epileptic patients receiving chronic anticonvulsant treatment. Psychopharmacology. 1986; 90(3):295-8. doi: 10.1007/bf00179180. [PMID: 3097715]
  • A Groppi, P Papa. One-step extraction procedure for gas chromatographic determination of viloxazine as its acetyl derivative in human plasma. Journal of chromatography. 1985 Jan; 337(1):142-5. doi: 10.1016/0378-4347(85)80020-7. [PMID: 3980644]
  • F Pisani, M C Narbone, A Fazio, P Crisafulli, G Primerano, A A D'Agostino, G Oteri, R Di Perri. Effect of viloxazine on serum carbamazepine levels in epileptic patients. Epilepsia. 1984 Aug; 25(4):482-5. doi: 10.1111/j.1528-1157.1984.tb03447.x. [PMID: 6745218]
  • A Fazio, P Crisafulli, G Primerano, A A D'Agostino, G Oteri, F Pisani. A sensitive gas chromatographic assay for the determination of serum viloxazine concentration using a nitrogen-phosphorus-selective detector. Therapeutic drug monitoring. 1984; 6(4):484-8. doi: 10.1097/00007691-198412000-00020. [PMID: 6515713]
  • A C Altamura, T Melorio, G Invernizzi, F Colacurcio, R Gomeni. Age-related differences in kinetics and side-effects of viloxazine in man and their clinical implications. Psychopharmacology. 1983; 81(4):281-5. doi: 10.1007/bf00427563. [PMID: 6419255]
  • B Vandel, S Vandel, J M Jounet, D Blum. Pharmacokinetics of viloxazine hydrochloride in man. European journal of drug metabolism and pharmacokinetics. 1982 Jan; 7(1):65-8. doi: 10.1007/bf03189545. [PMID: 7067726]
  • B S Meldrum, G M Anlezark, H K Adam, D T Greenwood. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology. 1982; 76(3):212-7. doi: 10.1007/bf00432547. [PMID: 6808538]
  • B Vandel, S Vandel, G Allers, R Volmat. Clinical pharmacology of viloxazine hydrochloride. Pharmacopsychiatria. 1981 Mar; 14(2):66-70. doi: 10.1055/s-2007-1019568. [PMID: 7232498]
  • R Gillilan, W D Mason. High-pressure liquid chromatographic determination of viloxazine in human plasma and urine. Journal of pharmaceutical sciences. 1981 Feb; 70(2):220-1. doi: 10.1002/jps.2600700227. [PMID: 7205231]
  • B Vandel, S Vandel, G Allers, F Grappe, R Volmat. [Comparative evolution of prolactin plasma levels during antidepressant treatment (author's transl)]. Therapie. 1981 Jan; 36(1):87-94. doi: NULL. [PMID: 7233377]
  • T R Norman, G D Burrows, B M Davies, K P Maguire, J M Wurm. Viloxazine plasma concentrations and clinical response. Journal of affective disorders. 1980 Sep; 2(3):157-64. doi: 10.1016/0165-0327(80)90002-6. [PMID: 6210721]
  • T R Norman, G D Burrows, B M Davies, J M Wurm. Determination of viloxazine in plasma by GLC. British journal of clinical pharmacology. 1979 Aug; 8(2):169-71. doi: 10.1111/j.1365-2125.1979.tb05816.x. [PMID: 486292]
  • B Müller-Oerlinghausen, E Rüther. Clinical profile and serum concentration of viloxazine as compared to amitriptyline. Pharmakopsychiatrie, Neuro-Psychopharmakologie. 1979 Jul; 12(4):321-37. doi: 10.1055/s-0028-1094627. [PMID: 386390]
  • C Loeb, G Roccatagliatà, G Besio. [Variations in the urinary level of MHPG in depressive syndromes]. Schweizer Archiv fur Neurologie, Neurochirurgie und Psychiatrie = Archives suisses de neurologie, neurochirurgie et de psychiatrie. 1979; 125(2):337-48. doi: NULL. [PMID: 555549]
  • R D Brosnan, A M Busby, R P Holland. Cases of overdosage with viloxazine hydrochloride (Vivalan). The Journal of international medical research. 1976; 4(2):83-5. doi: 10.1177/030006057600400201. [PMID: 1026544]
  • P F Bayliss, D E Case. Blood level studies with viloxazine hydrochloride in man. British journal of clinical pharmacology. 1975 Jun; 2(3):209-14. doi: 10.1111/j.1365-2125.1975.tb01577.x. [PMID: 1234502]
  • D E Case, P R Reeves. The disposition and metabolism of I.C.I. 58,834 (viloxazine) in humans. Xenobiotica; the fate of foreign compounds in biological systems. 1975 Feb; 5(2):113-29. doi: 10.3109/00498257509056097. [PMID: 1154799]